NASDAQ:FLXN

Flexion Therapeutics Stock Forecast, Price & News

Top-Rated Stocks

$11.54

+0.12 (+1.05 %)

(As of 01/22/2021 12:00 AM ET)

Add

Compare

Today's Range

$11.12

Now: $11.54▼

$11.61

50-Day Range

$10.83

MA: $11.83▼

$13.09

52-Week Range

$5.01

Now: $11.54▼

$18.87

Volume961,453 shs

Average Volume611,396 shs

Market Capitalization$569.10 million

P/E RatioN/A

Dividend YieldN/A

Beta1.64

Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201, a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, an administered NaV1.7 inhibitor for the management of post-operative pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.

MarketRank^™

Overall MarketRank^™

1.43 out of 5 stars

Medical Sector

517th out of 1,923 stocks

Pharmaceutical Preparations Industry

258th out of 773 stocks

3.5 Analyst's Opinion

Consensus Rating
Flexion Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $20.73, Flexion Therapeutics has a forecasted upside of 79.6% from its current price of $11.54.
Amount of Analyst Coverage
Flexion Therapeutics has only been the subject of 4 research reports in the past 90 days.

3.0 Community Rank

Outperform Votes
Flexion Therapeutics has received 550 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Flexion Therapeutics has received 362 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Flexion Therapeutics has received 60.31% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Flexion Therapeutics and other stocks. Vote “Outperform” if you believe FLXN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FLXN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Flexion Therapeutics does not currently pay a dividend.
Dividend Growth
Flexion Therapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Flexion Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $188,175.00 in company stock.
Percentage Held by Insiders
Only 17.03% of the stock of Flexion Therapeutics is held by insiders.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Flexion Therapeutics are expected to grow in the coming year, from ($2.60) to ($1.60) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Flexion Therapeutics is -3.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Flexion Therapeutics is -3.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:FLXN

Previous Symbol

CUSIPN/A

CIK1419600

Webwww.flexiontherapeutics.com

Phone781-305-7777

Employees288

Debt

Debt-to-Equity Ratio12.77

Current Ratio4.66

Quick Ratio4.31

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$72.96 million

Price / Sales7.80

Cash FlowN/A

Price / Cash FlowN/A

Book Value($0.53) per share

Price / Book-21.77

Profitability

EPS (Most Recent Fiscal Year)($3.93)

Net Income$-149,770,000.00

Net Margins-153.90%

Return on EquityN/A

Return on Assets-53.31%

Miscellaneous

Outstanding Shares49,315,000

Market Cap$569.10 million

Next Earnings Date3/11/2021 (Estimated)

OptionableOptionable

$11.54

+0.12 (+1.05 %)

(As of 01/22/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive FLXN News and Ratings via Email

Sign-up to receive the latest news and ratings for FLXN and its competitors with MarketBeat's FREE daily newsletter.

Flexion Therapeutics (NASDAQ:FLXN) Frequently Asked Questions

How has Flexion Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Flexion Therapeutics' stock was trading at $12.31 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, FLXN stock has decreased by 6.3% and is now trading at $11.54.
View which stocks have been most impacted by COVID-19.

Is Flexion Therapeutics a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Flexion Therapeutics in the last twelve months. There are currently 1 hold rating, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Flexion Therapeutics stock.
View analyst ratings for Flexion Therapeutics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Flexion Therapeutics?

Wall Street analysts have given Flexion Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Flexion Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Flexion Therapeutics' CEO?

1,448 employees have rated Flexion Therapeutics CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Flexion Therapeutics' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Flexion Therapeutics' next earnings date?

Flexion Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Flexion Therapeutics.

How were Flexion Therapeutics' earnings last quarter?

Flexion Therapeutics, Inc. (NASDAQ:FLXN) posted its quarterly earnings results on Wednesday, November, 4th. The specialty pharmaceutical company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by $0.01. The specialty pharmaceutical company had revenue of $23.66 million for the quarter, compared to the consensus estimate of $23.59 million.
View Flexion Therapeutics' earnings history.

What guidance has Flexion Therapeutics issued on next quarter's earnings?

Flexion Therapeutics issued an update on its FY 2020 Pre-Market earnings guidance on Wednesday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $85.5-85.5 million, compared to the consensus revenue estimate of $84.88 million.

What price target have analysts set for FLXN?

11 equities research analysts have issued 1 year price targets for Flexion Therapeutics' shares. Their forecasts range from $15.00 to $35.00. On average, they expect Flexion Therapeutics' stock price to reach $20.73 in the next twelve months. This suggests a possible upside of 79.6% from the stock's current price.
View analysts' price targets for Flexion Therapeutics or view Wall Street analyst' top-rated stocks.

Who are some of Flexion Therapeutics' key competitors?

Some companies that are related to Flexion Therapeutics include Stoke Therapeutics (STOK), Seres Therapeutics (MCRB), Praxis Precision Medicines (PRAX), Shattuck Labs (STTK), Harmony Biosciences (HRMY), PMV Pharmaceuticals (PMVP), NGM Biopharmaceuticals (NGM), Kura Oncology (KURA), Viela Bio (VIE), Prestige Consumer Healthcare (PBH), Revance Therapeutics (RVNC), Myovant Sciences (MYOV), Aurinia Pharmaceuticals (AUPH), Dicerna Pharmaceuticals (DRNA) and Kronos Bio (KRON).
View all of FLXN's competitors.

What other stocks do shareholders of Flexion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Flexion Therapeutics investors own include Regulus Therapeutics (RGLS), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Cara Therapeutics (CARA), Aduro Biotech (ADRO), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX) and Verastem (VSTM).

Who are Flexion Therapeutics' key executives?

Flexion Therapeutics' management team includes the following people:

Dr. Michael D. Clayman, Co-Founder, Pres, CEO & Director (Age 68, Pay $1.06M)
Dr. Neil Bodick, Consultant (Age 73, Pay $657.6k)
Dr. Scott D. Kelley, Chief Medical Officer (Age 61, Pay $626.53k)
Mr. David A. Arkowitz M.B.A., Chief Financial Officer (Age 59)
Scott Young, VP of Corp. Communications & Investor Relations
Ms. Carolyn Beaty Scimemi, VP, Legal Affairs & Chief Compliance Officer
Mr. Mark S. Levine, Gen. Counsel & Corp. Sec. (Age 47)
Mr. John Magee, VP of Sales
Ms. Christina Willwerth, Chief Strategy Officer (Age 49)
Ms. Kerry A. Wentworth, Chief Regulatory Officer (Age 47)

What is Flexion Therapeutics' stock symbol?

Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."

Who are Flexion Therapeutics' major shareholders?

Flexion Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (0.97%). Company insiders that own Flexion Therapeutics stock include Adam Muzikant, C Ann Merrifield, David Arkowitz, Mark S Levine, Mark Stejbach, Michael D Clayman and Samuel D Colella.
View institutional ownership trends for Flexion Therapeutics.

Which major investors are selling Flexion Therapeutics stock?

FLXN stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC. Company insiders that have sold Flexion Therapeutics company stock in the last year include Adam Muzikant, David Arkowitz, and Mark S Levine.
View insider buying and selling activity for Flexion Therapeutics or view top insider-selling stocks.

How do I buy shares of Flexion Therapeutics?

Shares of FLXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Flexion Therapeutics' stock price today?

One share of FLXN stock can currently be purchased for approximately $11.54.

How big of a company is Flexion Therapeutics?

Flexion Therapeutics has a market capitalization of $569.10 million and generates $72.96 million in revenue each year. The specialty pharmaceutical company earns $-149,770,000.00 in net income (profit) each year or ($3.93) on an earnings per share basis. Flexion Therapeutics employs 288 workers across the globe.

What is Flexion Therapeutics' official website?

The official website for Flexion Therapeutics is www.flexiontherapeutics.com.

How can I contact Flexion Therapeutics?

Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company can be reached via phone at 781-305-7777 or via email at [email protected]

This page was last updated on 1/24/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here